Core Viewpoint - Autonomix Medical, Inc. has released a video testimonial highlighting the effectiveness of transvascular nerve ablation in reducing pain for patients with severe pancreatic cancer, indicating a significant potential to improve quality of life in late-stage cancer care [2][3]. Company Overview - Autonomix Medical, Inc. is a medical device company focused on innovative technologies for diagnosing and treating diseases related to the nervous system [6][7]. - The company is developing a catheter-based microchip sensing array aimed at enhancing the detection and differentiation of neural signals, which may enable transvascular diagnosis and treatment of peripheral nervous system diseases [6][7]. Clinical Trial Insights - The initial phase of the first-in-human proof-of-concept trial (PoC 1) involved 20 patients with severe pancreatic cancer pain, demonstrating statistically significant pain relief as early as 24 hours post-procedure [3][5]. - Pain reduction was measured with a mean improvement of 4.16 on the Visual Analog Scale (VAS), representing a 53.3% improvement at 7 days post-procedure, and a mean reduction of 4.67 on the VAS, indicating a 59.2% improvement at 4-6 weeks post-procedure [3][5]. - 100% of responding patients achieved zero opioid use at 7 days post-procedure, with 73% remaining opioid-free at the 4-6 week follow-up [3][10]. Future Directions - Based on the positive outcomes from PoC 1, the company plans to expand the protocol into a follow-on phase (PoC 2), which will include pain management for additional visceral cancers and earlier-stage pancreatic cancer patients [3][4].